Surrozen (SRZN) AI Stock Analysis

• Market Cap: $342.99M
• Dividend Yield: N/A
• Average Volume (3M): 25.24K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.33
• Revenue Growth: -63.96%
• EPS Growth: -28.50%
• Country: US
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -19.13
• Shares Outstanding: 11,486,707
• 10 Day Avg. Volume: 29,706
• 30 Day Avg. Volume: 25,240
• PEG Ratio: -0.01
• Price to Book (P/B): -0.90
• Price to Sales (P/S): 48.61
• P/FCF Ratio: -5.56
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: 44.74
• Enterprise Value/Gross Profit: 45.32
• Enterprise Value/Ebitda: -1.52
• 1Y Price Target: $38.75
• Price Target Upside: 21.66% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -4.42
• Revenue Forecast (FY): $1.31M

• Rating: 47 Neutral
• Price Target: $29.00 ▼(-8.95% Downside)
• Action: Reiterated Date: 03/24/26
• Date: Action: Reiterated 03/24/26

The score is primarily held down by weak financial performance (volatile revenue, ongoing losses/cash burn, and negative equity indicating elevated funding risk). Technicals provide some support with price above longer-term averages and modestly positive MACD, but valuation remains difficult to justify with a negative P/E and no dividend yield.

Positive Factors

Platform / Scientific Focus

Surrozen's core platform targets Wnt signaling to stimulate tissue repair across organs (liver, intestine, eye). A mechanism-focused platform that addresses fundamental biology can yield multiple programs and durable value if clinical proof establishes a reproducible regenerative approach.

Negative Factors

Negative equity / balance-sheet fragility

Equity turning materially negative is a structural red flag: it weakens financial flexibility, limits borrowing capacity, and raises likelihood of dilutive financing or restrictive deal terms. This elevates execution risk for multi-year clinical development programs.

Surrozen Business Overview & Revenue Model

Company Description

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, ...

Read more

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, ...

How the Company Makes Money

Surrozen does not primarily generate revenue from product sales because it is a clinical-stage biotechnology company and, to the extent publicly available information indicates, it has no approved commercial products. Instead, when it earns revenu...

Read more

Surrozen does not primarily generate revenue from product sales because it is a clinical-stage biotechnology company and, to the extent publicly available information indicates, it has no approved commercial products. Instead, when it earns revenu...

Surrozen Financial Statement Overview

Breakdown	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.48M	10.65M	0.00	12.50M	0.00
Gross Profit	2.94M	10.65M	-27.23M	9.23M	-3.30M
EBITDA	-41.55M	-24.10M	-41.13M	-42.38M	-51.35M
Net Income	-242.03M	-63.56M	-43.04M	-36.00M	-52.51M
Balance Sheet
Total Assets	98.73M	48.47M	46.08M	89.44M	137.17M
Cash, Cash Equivalents and Short-Term Investments	89.25M	34.56M	36.04M	75.84M	101.85M
Total Debt	6.64M	8.47M	3.38M	5.60M	7.79M
Total Liabilities	286.49M	69.85M	8.14M	13.43M	27.47M
Stockholders Equity	-187.76M	-21.38M	37.94M	76.00M	109.70M
Cash Flow
Free Cash Flow	-30.37M	-17.65M	-40.76M	-44.87M	-50.08M
Operating Cash Flow	-30.24M	-17.63M	-40.36M	-44.15M	-48.81M
Investing Cash Flow	-128.00K	-26.00K	51.72M	38.31M	-77.71M
Financing Cash Flow	85.05M	16.18M	276.00K	-2.56M	124.63M

Surrozen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 31.85
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRZN, the sentiment is Positive. The current price of 31.85 is above the 20-day moving average (MA) of 27.28, above the 50-day MA of 26.26, and above the 200-day MA of 17.20, indicating a bullish trend. The MACD of 0.92 indicates Negative momentum. The RSI at 67.10 is Neutral, neither overbought nor oversold. The STOCH value of 83.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRZN.

Surrozen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	56 Neutral	$367.93M	-6.90	-23.98%	―	946.61%	-11.30%
BMEA	54 Neutral	$135.92M	4.86	-209.00%	―	―	40.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IRD	50 Neutral	$396.30M	-25.22	-452.26%	―	74.60%	-58.14%
STTK	50 Neutral	$495.22M	―	-65.03%	―	-84.46%	33.32%
SRZN	47 Neutral	$342.99M	-0.70	―	―	-63.96%	-28.50%
SPRB	47 Neutral	$88.51M	-1.71	-305.39%	―	-90.18%	-17.93%

Surrozen Corporate Events